83 related articles for article (PubMed ID: 1342235)
21. Somatostatin analogue SMS 201-995 in type I diabetes mellitus. Initial experience after repeated administration.
Plewe G; Nölken G; Krause U; del Pozo E; Beyer J
Scand J Gastroenterol Suppl; 1986; 119():166-9. PubMed ID: 2876502
[TBL] [Abstract][Full Text] [Related]
22. Pretreatment with somatostatin analog SMS 201-995 potentiates growth hormone (GH) responsiveness to GH-releasing factor in short children.
Dickerman Z; Guyda H; Tannenbaum GS
J Clin Endocrinol Metab; 1993 Sep; 77(3):652-7. PubMed ID: 8257527
[TBL] [Abstract][Full Text] [Related]
23. Efficacy, pharmacokinetics and tolerability of a somatostatin analogue (L-363,586) in insulin-dependent diabetes mellitus.
Gottesman I; Tobert J; Vandlen R; Gerich J
Life Sci; 1986 Jun; 38(24):2211-9. PubMed ID: 2872569
[TBL] [Abstract][Full Text] [Related]
24. Suppression of growth hormone and somatomedin C by long-acting somatostatin analog SMS 201-995 in type I diabetes mellitus.
Plewe G; Noelken G; Krause U; Beyer J; del Pozo E
Horm Res; 1987; 27(1):7-12. PubMed ID: 2887504
[TBL] [Abstract][Full Text] [Related]
25. Severe hypoglycemia as a short-term side-effect of the somatostatin analog SMS 201-995 in insulin-dependent diabetes mellitus.
Navascuès I; Gil J; Pascau C; Senen D; Serrano-Rios M
Horm Metab Res; 1988 Dec; 20(12):749-50. PubMed ID: 3065203
[TBL] [Abstract][Full Text] [Related]
26. Effects of SMS 201-995 on intermediary metabolism and endocrine status in normal and diabetic humans.
Johnston DG; Davies RR; Alberti KG; Miller M; Turner SJ; Watson M; Orskov H
Am J Med; 1986 Dec; 81(6B):88-93. PubMed ID: 2879452
[TBL] [Abstract][Full Text] [Related]
27. Effects of somatostatin analogue SMS 201-995 in non-insulin-dependent diabetes.
Davies RR; Miller M; Turner SJ; Watson M; McGill A; Orskov H; Alberti KG; Johnston DG
Clin Endocrinol (Oxf); 1986 Dec; 25(6):739-47. PubMed ID: 2888547
[TBL] [Abstract][Full Text] [Related]
28. Preventive effects of octreotide (SMS 201-995) on diabetic ketogenesis during insulin withdrawal.
Diem P; Robertson RP
Br J Clin Pharmacol; 1991 Nov; 32(5):563-7. PubMed ID: 1954071
[TBL] [Abstract][Full Text] [Related]
29. Treatment of the dumping syndrome with the somatostatin analogue SMS 201-995.
Hopman WP; Wolberink RG; Lamers CB; Van Tongeren JH
Ann Surg; 1988 Feb; 207(2):155-9. PubMed ID: 2893592
[TBL] [Abstract][Full Text] [Related]
30. Somatostatin analog octreotide (SMS 201-995) prevents the decrease in blood pressure after oral glucose loading in the elderly.
Jansen RW; Peeters TL; Lenders JW; van Lier HJ; v't Laar A; Hoefnagels WH
J Clin Endocrinol Metab; 1989 Apr; 68(4):752-6. PubMed ID: 2646315
[TBL] [Abstract][Full Text] [Related]
31. Effect of insulin concentration on bioavailability during nasal spray administration.
Valensi P; Zirinis P; Nicolas P; Perret G; Sandre-Banon D; Attali JR
Pathol Biol (Paris); 1996 Apr; 44(4):235-40. PubMed ID: 8763584
[TBL] [Abstract][Full Text] [Related]
32. Treatment of postprandial hypotension with a somatostatin analogue (SMS 201-995).
Hoeldtke RD; Boden G; O'Dorisio TM
Am J Med; 1986 Dec; 81(6B):83-7. PubMed ID: 2879451
[TBL] [Abstract][Full Text] [Related]
33. Effect of long-acting somatostatin analog (SMS 201-995) on high glomerular filtration rate in insulin dependent diabetic patients.
Krempf M; Ranganathan S; Remy JP; Charbonnel B; Guillon J
Int J Clin Pharmacol Ther Toxicol; 1990 Jul; 28(7):309-11. PubMed ID: 2387655
[TBL] [Abstract][Full Text] [Related]
34. Treatment of severe reactive hypoglycemia with a somatostatin analogue (SMS 201-995).
Lehnert H; Beyer J; Weber P; Krause U; Schrezenmeir J
Arch Intern Med; 1990 Nov; 150(11):2401-2. PubMed ID: 2241454
[TBL] [Abstract][Full Text] [Related]
35. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
[TBL] [Abstract][Full Text] [Related]
36. Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients.
Nathan DM; Dunn FL; Bruch J; McKitrick C; Larkin M; Haggan C; Lavin-Tompkins J; Norman D; Rogers D; Simon D
Am J Med; 1996 Apr; 100(4):412-7. PubMed ID: 8610727
[TBL] [Abstract][Full Text] [Related]
37. Influence of octreotide (SMS 201-995) and insulin administration on the course of blood pressure after an oral glucose load in hypertensive elderly subjects.
Jansen RW; de Meijer PH; van Lier HJ; Hoefnagels WH
J Am Geriatr Soc; 1989 Dec; 37(12):1135-9. PubMed ID: 2687350
[TBL] [Abstract][Full Text] [Related]
38. [The absorption of short-acting insulin administered subcutaneously in diabetic patients].
Nakamura T; Sekino K; Kasai F; Ishii F; Kudoo M; Imamura K; Kikuchi N; Takebe K
Probl Endokrinol (Mosk); 1993; 39(2):14-6. PubMed ID: 8016042
[No Abstract] [Full Text] [Related]
39. Intravenous and subcutaneous administration of a long-acting somatostatin analogue: effects on glucose metabolism and splanchnic haemodynamics in healthy subjects.
Eriksson LS; Wahren J
Eur J Clin Invest; 1989 Apr; 19(2):213-9. PubMed ID: 2499481
[TBL] [Abstract][Full Text] [Related]
40. Mixing short and intermediate acting insulins in the syringe: effect on postprandial blood glucose concentrations in type I diabetics.
Heine RJ; Bilo HJ; Sikkenk AC; van der Veen EA
Br Med J (Clin Res Ed); 1985 Jan; 290(6463):204-5. PubMed ID: 3917752
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
